Last April, as the world fell to Covid-19, one Chinese company was there to offer a helping hand: BGI. But the line between the biotech giant and Beijing is increasingly blurry.
Listen to SupChina editor-at-large and Sinica podcast host Kaiser Kuo read this article.
On January 25, 2020, as the city of Wuhan headed into the world’s first Covid-19 lockdown, the Chinese billionaire Wang Jian arrived on one of the last incoming trains. Flanked by a small entourage of younger scientists, Wang exited the station wearing a mask, a light puffy jacket and a backpack. Thousands were fleeing the river port metropolis. But Wang came ready to work.
During the SARS epidemic in 2003, the now 66-year-old geneticist had been similarly proactive, repeatedly flying to the outbreak’s epicenter in Guangdong Province to petition authorities to allow his young bioscience firm, the Beijing Genomics Institute (BGI), to sequence the deadly respiratory virus’s genome. Wang’s requests were denied until the last moment, after SARS reached Canada and scientists there became the first to sequence it — a national embarrassment for a rising China. BGI ev
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Quantum technologies have long sounded like they belong in the realm of science fiction. But in recent years, China, led by the brilliant physicist Pan Jianwei, has made huge quantum strides. Now, recent U.S. sanctions targeting Chinese quantum companies underscore the reality that these technologies are no longer theoretical.
